Context: Understanding intersubject variability in glycemic control following exercise training will help individualize treatment.
R
andomized controlled trials have shown that aerobic exercise training improves glycemic control in subjects with impaired glucose tolerance and type 2 diabetes (1) (2) (3) (4) (5) . However, the HERITAGE Family Study found that the interindividual variability in the response to exercise is large (6) . The natural progression of type 2 diabetes indicates that as insulin sensitivity deteriorates, pancreatic ␤ cells initially compensate by secreting more insulin but, with time, compensatory hyperinsulinemia fails and hyperglycemia ensues (7) . Although several exercise studies have focused attention on changes in insulin sensitivity, fewer have examined the role of insulin secretion. Traditionally, after exercise in nondiabetic subjects, insulin secretion is reduced relative to an increase in insulin sensitivity; but in type 2 diabetes, where ␤-cell function may be very poor, exercise training increases insulin secretion in the presence of increased insulin sensitivity (8 -10) . However, to evaluate the true clinical effect of exercise, glycemic control should be determined because measuring insulin sensitivity or insulin secretion alone does not indicate the state of glycemic control; such variables are simply mechanistic entities that govern glucose tolerance.
In our previous studies, comparisons of group means have shown statistically significant improvements in glycemia following exercise (5, 8, 11) . However, like the HERITAGE study, we have consistently observed large intersubject variability. We recently reported that in nondiabetic subjects, impaired fasting glucose blunted the beneficial effect of exercise on glycemic control (12) . We have also shown that among subjects with type 2 diabetes, high ambient hyperglycemia (hemoglobin A 1c ) predicts smaller improvements in glycosylated hemoglobin (HbA 1c ) following exercise (5, 13) . Although data from the HERITAGE study show that exercise training-induced changes in fitness (14, 15) and glycemic control (16) in healthy subjects may be influenced by the skeletal muscle transcriptome, studies in subjects with dysregulated glycemic control indicate that pancreatic ␤-cell function may also play a role. For example, obese nondiabetic subjects exposed to diet-induced elevations in daytime glycemia exhibited a worsening of hyperinsulinemia following exercise training compared to those with lower daytime glycemia (17) . Furthermore, Dela et al (9) demonstrated that subjects with type 2 diabetes who had poorer insulin secretory capacity and overt hyperglycemia exhibited a blunted exercise training-induced improvement in glycemic control and glucose-stimulated insulin secretion (GSIS). Accordingly, Krotkiewski et al (10) showed that lower baseline GSIS in type 2 diabetes predicted a smaller increment in GSIS following exercise training. These findings indicate that pancreatic ␤-cell function may influence exercise training-induced changes in glycemic control; however, a thorough examination of this concept has not been conducted.
The main purpose of this study was to determine the individual exercise-responsiveness (postminus pretraining change) of glycemic control and the underlying changes in insulin sensitivity and insulin secretion in a large cohort of subjects with dysregulated glucose tolerance, under the hypothesis that changes in ␤-cell function would be a major determinant of the training-induced improvement in glycemic control.
Materials and Methods

Subjects
This study includes individual subject data from those who had adhered to Ͼ90% of the prescribed exercise training, so as to remove the confounding effects of exercise volume. As such, this is a nonrandomized, single-arm intervention. It should also be noted that data from some of the subjects have been used previously to test hypotheses related to exercise training and insulin resistance (5, 11) . Potential subjects from the local community underwent medical evaluation (medical history, physical examination, 75 g oral glucose tolerance test [OGTT] , and blood chemistry) as part of eligibility screening. Volunteers engaged in regular exercise or weight loss programs, smokers, pregnant women, and those exhibiting symptoms of chronic pulmonary/ hepatic/renal/cardiovascular/hematological disease were excluded from participation. All subjects had impaired glucose tolerance or type 2 diabetes according to American Diabetes Association criteria (18) . Participants with type 2 diabetes were recently diagnosed (4.8 Ϯ 0.9 y) and those who were previously diagnosed were being treated with antidiabetic medications (metformin [N ϭ 14], sulfonylureas [N ϭ 6], GLP-1-analogues [N ϭ 2], and DPP-4-inhibitors [N ϭ 1]). None of these subjects were receiving insulin therapy. Medications were withheld for 5 days prior to metabolic testing. All female subjects were postmenopausal. The study was approved by the Institutional Review Board at the Cleveland Clinic (Cleveland, Ohio) and by the Ethical Committee of the Capital Region of Denmark. All subjects provided informed consent before participation in the study.
Measurements
For 3 days prior to testing, subjects continued their typical dietary/activity habits and completed diet and exercise records. Clinical assessments were conducted at the Clinical Research Unit at the Cleveland Clinic and in the clinical research laboratory of the Centre of Inflammation and Metabolism (Copenhagen, Denmark). Body composition (height, weight, dual-energy x-ray absorptiometry to determine body fat) and aerobic fitness (VO 2 max measured during an incremental workload exercise test to exhaustion on a treadmill; details in Ref. 11) were measured. Glycemic control was determined by HbA 1c (samples were collected in 54 subjects), fasting plasma glucose, the 2-hour glucose response to a standard 75 g OGTT, and incremental area under the glucose response curve during OGTT. Blood samples were collected at 0, 30, 60, 90, and 120 minutes during OGTT. Insulin sensitivity was measured using a 2-hour hyperinsulinemic (40 mU/m 2 /min) euglycemic (5 mM) clamp, using the method described by DeFronzo et al (19) . Subjects with fasting glucose greater than 5 mM underwent a prolonged (Ͻ1 h) priming infusion of insulin to reduce glucose levels to 5 mM before exogenous glucose was administered. Oral GSIS was assessed by serum insulin and C-peptide responses during OGTT. All tests were conducted at baseline and repeated 2 to 4 days after the final exercise bout.
Intervention
All subjects participated in an aerobic exercise training intervention of 12 to 16 weeks in duration. Exercise consisted of treadmill walking or cycle ergometry performed for ϳ60 minutes per day, on 4 to 5 days per week, at an intensity of ϳ75% of VO 2 max. VO 2 max was measured every 2 to 4 weeks during the intervention to modify the absolute work load of exercise so as to maintain the appropriate relative intensity. Full details of our standard exercise intervention are published (5, 17) .
Calculations
Insulin sensitivity was quantified as the mean steady-state rate of glucose disposal during the final 30 minutes of the glucose clamp divided by the mean steady-state plasma insulin (Si; mol/ kg/min/pM). Incremental area under the curve (AUC) (iAUC) for glucose (mM.min), insulin (pM.min), and C-peptide (pM.min) during OGTT was calculated using the trapezoid method. Firstphase GSIS is the incremental insulin and C-peptide response during the first 30 minutes of OGTT (⌬0 -30 min). Second-phase GSIS equals iAUC for insulin and C-peptide during 30 to 120 minutes of the OGTT. Insulin secretion rate sensitivity to changes in glucose (rate sensitivity) is defined as the average C-peptide response above basal over the average glucose stimulus above basal (20) . Disposition index (DI), a measure of pancreatic ␤-cell insulin secretory compensation for deteriorating insulin sensitivity, and which reflects whole-body glucose disposition, was calculated as the product of (first-and secondphase) GSIS and Si, in accordance with prior work (21) . Validation of the inverse relationship between GSIS and insulin sensitivity is provided in the Supplemental Methods and Supplemental Table 1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org.
Biochemical analyses
HbA 1c was measured in whole blood by high-pressure liquid chromatography (Tosho G7). Samples for glucose analysis were collected into heparin-containing syringes and immediately analyzed (YSI Stat; ABL 700, Radiometer). Samples for C-peptide and insulin analyses were collected into plain blood tubes at room temperature and centrifuged immediately at 25°C for 15 minutes at 2000g. Sera were isolated and stored at Ϫ80°C until analysis by electrochemiluminescence immunoassay (E-modular, Roche).
Statistics
Exercise training-induced changes between pre-and postintervention means were examined using paired two-tailed t tests. In this study we define exercise responsiveness as the exerciseinduced change (⌬; ⌬ ϭ postminus pretraining mean). Relationships between intervention-induced changes in variables were determined by linear regression. Furthermore, relationships between the preintervention value and its corresponding intervention-induced change were also demonstrated using linear regression. Age, body mass index (BMI), sex, and time since diagnosis had no influence on the statistical outcomes from these regression analyses. Family history of diabetes was not recorded and thus not controlled for. Statistical analyses were conducted using Prism v6 (GraphPad) and SPSS v20 (IBM), and statistical significance was accepted when P Ͻ .05. All data represent mean Ϯ SEM unless stated otherwise. 
Results
Subjects
One hundred five older (61 Ϯ 1 y) overweight/obese (BMI 33 Ϯ 1 kg/m 2 ) subjects were included in this observational study (Table 1) . Fifty-six subjects had impaired glucose tolerance and 49 had type 2 diabetes. Mean adherence to the intervention was 94 Ϯ 1% (ϭ total exercise minutes performed divided exercise minutes prescribed).
Effects of exercise training on physiological and metabolic outcomes (Table 1) Body weight, BMI, and whole body adiposity were significantly decreased (Ϫ5 Ϯ 1%) following exercise. Aerobic fitness was increased by ϩ11 Ϯ 1%. There was a significant reduction in several measures of glycemic control (fasting glucose, 2-h OGTT glucose, and AUC glucose); however, mean HbA 1c was unchanged between preand postexercise. Serum insulin concentrations (fasting and during OGTT) decreased following exercise, whereas serum C-peptide levels during OGTT were unchanged. GSIS was reduced following exercise when calculated using serum insulin levels, but not when GSIS was calculated using C-peptide levels. There was a 60 Ϯ 9% increase in insulin-sensitivity following exercise, and a 69 Ϯ 15% and 82 Ϯ 14% increase in first-and second-phase DI.
Intersubject exercise responsiveness
Following exercise, 86% of subjects increased VO 2 max ( Figure 1A ), 86% lost weight ( Figure 1B) , and 77% reduced whole-body adiposity ( Figure 1C ). Exercise reduced HbA 1c ( Figure 1D ), fasting plasma glucose ( Figure  1E ), 2-hour plasma glucose during OGTT ( Figure 1F ), and AUC plasma glucose during OGTT in 69%, 62%, 68%, and 54% of subjects. Insulin-stimulated glucose disposal was increased following exercise in 90% of subjects (Figure 1G ), but the training-induced changes in insulin secretion were less consistent: fasting C-peptide ( Figure 1H ) and 2-hour OGTT C-peptide ( Figure 1I ) were both decreased in 60% of the subjects, whereas 59% of subjects had a decrease in the incremental 30-minute C-peptide response to oral glucose, and insulin secretion rate sensitivity to changes in plasma glucose was reduced in 51% of subjects. First-and second-phase GSIS was decreased in 66% and 46% of subjects and first-and second-phase DI was increased in 83% and 74% of subjects ( Figure 2) . Additional exercise-responsiveness data, including trends in serum insulin, are provided in Supplemental Figure 1 .
Relationship between training-induced changes in glycemic control and training-induced changes in insulin sensitivity or ␤-cell function Table 2 indicates that exercise training-induced changes in ambient hyperglycemia (HbA 1c and fasting plasma glucose) and measures of oral glucose tolerance (2-h glucose and AUC glucose during OGTT) were significantly correlated with training-induced changes in various markers of insulin secretion, but they were not related to training-induced changes in insulin sensitivity. For example, a larger increase in first-and second-phase GSIS was correlated with a better reduction in 2-hour OGTT glucose ( Figure 3, A and B) . Weight loss was related to training-induced changes in fasting and 2-hour OGTT glucose (both r ϭ 0.22, P Ͻ .05), fasting C-peptide (r ϭ 0.32, P Ͻ .01), insulin sensitivity (r ϭ Ϫ0.61, P Ͻ .001), and DI (r ϭ Ϫ0.57, P Ͻ .001); however, the correlations between training-induced changes in glycemic control and insulin secretion remained significant when controlling for weight loss.
Predicting training-induced changes in glycemic control, insulin sensitivity, or ␤-cell function from pretraining metabolic or endocrine variables
Pretraining measures of glycemic control were inversely correlated with training-induced increases in insulin sensitivity and first-and second-phase DI, such that high pretraining HbA 1c (r ϭ Ϫ0.50 and Ϫ0.51), fasting were measured as the postminus preexercise (⌬) values. Individual subject data points are plotted on the x-axis. Y-axis data above the origin indicate an exercise training-induced increase in that variable; data below the origin represent a training-induced decrease. First-phase GSIS is reported as the area under the serum C-peptide response curve during the first 30 minutes following the ingestion of 75 g glucose. Second-phase GSIS is reported as the area under the C-peptide curve from 30 to 120 minutes after glucose ingestion. DI is calculated as the product of GSIS and insulin sensitivity.
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glucose (r ϭ Ϫ0.40 and Ϫ0.44), 2-hour OGTT glucose (r ϭ Ϫ0.49 and Ϫ0.55), and area under the OGTT glucose curve (r ϭ Ϫ0.50 and Ϫ0.52) predicted smaller increases in these variables (all P Ͻ .001) ( Figure 3 , E and F). Longer type 2 diabetes disease duration (y) also predicted poorer training-induced decreases in 2-hour OGTT glucose (r ϭ 0.40, P Ͻ .01) and area under the OGTT glucose curve (r ϭ 0.53, P Ͻ .001), and poorer increases in insulin sensitivity (r ϭ Ϫ0.36, P Ͻ .05), and second-phase DI (r ϭ Ϫ0.41, P Ͻ .05). Furthermore, pretraining markers of ␤-cell insulin secretory function were inversely associated with training-induced decreases in glycemic control, such that high pretraining 2-hour OGTT C-peptide and firstphase GSIS predicted a greater training-induced decrease in 2-hour OGTT glucose (r ϭ Ϫ0.31, P Ͻ .01; and r ϭ Ϫ0.28, P Ͻ .05) and area under the OGTT glucose curve (r ϭ Ϫ0.36, P Ͻ .01; and r ϭ Ϫ0.27, P Ͻ .05) (Figure 3 , C and D). Although pretraining insulin secretory function predicted changes in glycemic control, on the contrary, pretraining insulin sensitivity was not associated with training-induced changes in any variable (all comparisons, P Ͼ .05).
Discussion
We observed that regular aerobic exercise training improved aerobic fitness and body composition and increased insulin-mediated peripheral tissue glucose disposal in 86% to 90% of subjects. However, despite these beneficial effects in most subjects, glycemic control (HbA1c, fasting glucose, or oral glucose tolerance) improved in only two-thirds of subjects. This high intersubject variability in the exercise responsiveness of glycemic control was visually reflected by the intersubject variability in exercise training-induced changes in glucose-stimulated insulin secretion. We confirmed this objectively, demonstrating that training-induced changes in glycemic control were correlated with changes in insulin secretion; we found that high pretraining glucose-stimulated insulin secretory capacity predicted better training-induced improvements in glycemic control. In addition, although training-induced changes in DI were not related to changes in glycemic control, the DI was significantly increased following exercise and, interestingly, high ambient hyperglycemia before commencing training blunted training-induced improvements in the DI. These data emphasize the large intersubject variability that exists in the exercise responsiveness of glycemic control. Previously, we documented that high ambient hyperglycemia in subjects with type 2 diabetes blunts the beneficial effect of aerobic exercise on glycemic control in that high HbA 1c or 2-hour OGTT glucose predicts poor improvements in glycemic control following training (13) . The Look-AHEAD study also recently showed that dia- ) and (B) demonstrate that a greater training-induced increase in first-and second-phase GSIS (x-axis) was related to a greater training-induced decrease in 2-hour plasma glucose measured during OGTT (y-axis). (C) and (D) indicate that larger preintervention first-and second-phase GSIS (x-axis) were associated with larger training-induced improvements in oral glucose tolerance (y-axis). (E) and (F) show that poorer preintervention glycemic control, as indicated by high HbA 1c (x-axis), was correlated with poorer training-induced improvements in the DI (y-axis). First-phase GSIS is measured as the area under the serum C-peptide response curve during the first 30 minutes following the ingestion of 75 g glucose. Second-phase GSIS is measured as the area under the C-peptide curve from 30 to 120 minutes after glucose ingestion. DI is calculated as the product of GSIS and insulin sensitivity.
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betes remission following exercise and diet intervention was more likely in persons with diabetes with a shorter disease history and lower initial HbA 1c (22) . Given that following a single exercise bout van Dijk et al (23) showed greater reductions in daytime glycemia in type 2 diabetes patients with higher HbA 1c , these poorer outcomes following exercise training in more hyperglycemic diabetic subjects are perhaps unexpected. However, such observations are supported by prior evidence from us (12, 17) and others (9, 10), which have indicated that poor pretraining glycemic control may predict the effectiveness of exercise, and this may all depend on ␤-cell capacity at the time the intervention is initiated. Our new data complement prior evidence in that low pretraining GSIS (2-h OGTT C-peptide, and first-and second-phase C-peptide response to OGTT) predicted smaller training-induced decreases in glycemia (2-h and AUC OGTT glucose). Furthermore, high ambient hyperglycemia (HbA 1c and fasting glucose) and poor glucose tolerance (OGTT) also predicted a poorer training-induced increase in the DI. The DI provides a measure of compensatory ␤-cell function (glucosestimulated insulin secretion) relative to changes in the underlying degree of insulin sensitivity (insulin-stimulated glucose disposal) and in absolute terms indicates wholebody glucose disposition. It is therefore not just a measure of GSIS and is therefore not solely a measure of ␤-cell function. Also by nature of its calculation, changes in insulin sensitivity carry as much weight to the change in DI as do changes in insulin secretion. We found a significant increase in DI following training in a population of subjects representing both impaired glucose tolerant and type 2 diabetic phenotypes, where population means for insulin sensitivity were significantly increased (Table 2 ) and where population means for insulin secretory function were unchanged (Table 2 ). In this context, an increase in the DI value is primarily driven by the increment in insulin sensitivity. Accordingly, the variability in the training-induced change in DI is similar to the observed variability in insulin sensitivity ( Figure 1 ). As such, DI is consistently increased following training in most subjects (83% and 74% of subjects for first-and second-phase DI, respectively); however, it was a poor predictor of the exerciseinduced change in glycemic control (Table 3) .
Despite showing significant improvements in insulin sensitivity, our observations that training-induced changes in glycemic control are related to changes in insulin secretion but not insulin sensitivity. Accordingly, we noted that higher pretraining GSIS predicts larger training-induced decreases in glucose tolerance, which adds to the evidence from Dela et al (9) that some residual ␤-cell function is required to maximize the beneficial effect of aerobic exercise on glycemic control. Decreased capacity to secrete insulin may be explained by the profound degree of glucotoxicity that exists in subjects with type 2 diabetes. Prolonged exposure to glucose can impair pancreatic ␤-cell function in vitro (reviewed in Refs. [24, 25] ), and we (26) and others (27, 28) have demonstrated this experimentally in vivo. In ␤ cells, it is likely that increased IL-1␤ signaling leads to insulin secretory dysfunction and cell death in type 2 diabetic models (29) . Interestingly, Russell et al (30) provide in vitro evidence that IL-6 augments apoptosis in pancreatic ␤ cells under IL-1␤-mediated inflammatory attack. This is of relevance to the exercise setting because there is a well-documented acute and transient inflammatory response (increased muscle-derived plasma IL-6) to a single exercise bout (31) . Thus, we speculate that accumulation of multiple exercise bouts exposes the endocrine pancreas to increased amounts of IL-6, which under conditions of glucolipotoxicity-induced inflammation (IL-1␤) such as found in uncontrolled type 2 diabetes may augment ␤-cell death and subsequent insulin secretory dysfunction. Our unpublished in vitro data support this speculation, but further in vivo investigation is warranted.
The observation that ϳ30% of subjects experienced a deterioration in glycemic control (when assessed by HbA 1c , fasting glucose, or 2-h glucose) following exercise is concerning. This lack of a therapeutic benefit of exercise on glycemic control is also highlighted by the finding that mean values of HbA 1c were not significantly changed between pre-and postintervention time points (Table 1) , although this is possibly explained by the relatively shortterm nature of the intervention (12-16 wk) . This does however provide a good example that important information regarding individualized subject responses to treatments may be masked if only changes in group means are considered. This adverse effect of exercise on glycemic control was documented in the HERITAGE Study by Boulé and colleagues (6) , whereby ϳ40% of subjects decreased iv glucose tolerance. That study and ours are of relatively short duration (Ͻ20 wk) and outcomes of diabetic complications and diabetes-related mortality were not measured so it is difficult to comment on the long-term implications of these adverse effects on glycemic control. Promisingly, other data from the HERITAGE study showed that only 7% of participants exhibited deterioration in two or more components of the metabolic syndrome (32) , suggesting that the impact of exercise responsiveness on the variability of cardiovascular disease risk may be small. Nevertheless, the clinical relevance of these findings is paramount, as they point toward the need for future research to gain insight mechanistically to the metabolic "nonresponder." Ultimately, this understanding will potentially lead to the personalization of medical treatment and help maximize the benefit of physical activity.
We appreciate that correlations do not indicate causality. Future randomized controlled trials stratifying subjects by glycemia will determine whether our observations extrapolate to causal associations. Additional assessments of ␤-cell function are also warranted; for instance, insulin secretory responses to nonglucose secretagogues (incretins, arginine). However, other variables may be implicated. For example, the HERITAGE Study noted that the presence of a single (Pro12Ala) nucleotide polymorphism in peroxisome proliferator-activated receptor-␥ increased training-induced improvements in glucose tolerance (16) . Furthermore, metformin, a widely prescribed antihyperglycemic drug, may interact with exercise to impair outcomes regarding insulin sensitivity (33) (34) (35) . In this study, genomic/transcriptomic analyses were not performed; however, antidiabetic medications (N ϭ 14 metformin, N ϭ 6 sulfonylureas, N ϭ 2 GLP-1-analogues, N ϭ 1 DPP-4-inhibitors) did not influence our outcomes; due to the small sample size, such analyses may be underpowered. Weight loss may also impact our outcome variables, and although training-induced weight loss was related to changes in fasting glucose (r ϭ 0.23, P Ͻ .05) and insulin sensitivity (r ϭ 0.61, P Ͻ .001) but no other measure related to glycemic control, baseline body weight did not predict exercise responsiveness of any variable. One final comment regarding our design is that changes in the groups' mean values for serum insulin but not C-peptide were found following exercise, indicating that hepatic insulin extraction was likely increased following training. This variable was not measured directly and is often neglected in exercise studies. Future work should consider hepatic insulin extraction as a variable of interest.
Future studies should incorporate a thorough clinical assessment of glycemic control to include HbA 1c , fasting glucose, and an OGTT, so that appropriate expectations regarding the clinical effectiveness of exercise training can be drawn. Despite consistent improvements in fitness, body composition, and insulin sensitivity, there is high intersubject variability in the improvement of glycemic control following aerobic exercise training. This finding makes it clear that despite observing statistically significant improvements in insulin sensitivity, great caution should be taken when assuming that exercise training has a clinically meaningful outcome with regard to glycemic control. Herein we demonstrate that the intersubject variability in the exercise responsiveness of glycemic control is related to variability in exercise training-induced changes in insulin secretion, and that high pretraining ambient hyperglycemia and low insulin secretory function predict a poorer training-induced outcome. Hence, using aerobic exercise to treat patients with poorly controlled long-term type 2 diabetes may have limited chances of a successfully controlled glycemia. In such patients it seems sensible to improve ␤-cell function and achieve better glycemic control (possibly by pharmaceutical means) prior to incorporating aerobic exercise as an intervention. Future randomized controlled trials are crucial to determine an optimal approach. Overall, these findings are important in that they highlight the need for individualized treatment so as to maximize the benefit to treating obesity-related hyperglycemia.
